Low Prevalence of the Somatic M918T RET Mutation in Micro-Medullary Thyroid Cancer
- 1 May 2012
- journal article
- research article
- Published by SAGE Publications in Thyroid®
- Vol. 22 (5) , 476-481
Abstract
Background: The prevalence of RET somatic mutations in sporadic medullary thyroid cancer (MTCs) is ∼40%–50%, and the most frequent somatic mutation is M918T. RET-positive MTCs have been demonstrated to have a more advanced stage at diagnosis and a worse outcome. Aims: The aim of the present work was to compare the prevalence of RET somatic mutations in sporadic microMTCs (Patients: We analyzed the M918T RET point mutation in 160 sporadic MTC cases. Tumors were classified according to their size: group A, 1 and 2 and 3 cm. Results: The overall prevalence of the somatic M918T RET mutation was 19.4% (31/160). RET mutations were distributed differently among the four groups. The prevalence was 11.3% (6/53) in group A, 11.8% (8/68) in group B, 31.8% (7/22) in group C, and 58.8% (10/17) in group D, exhibiting an increase with increasing size of the tumor. When comparing the prevalence of mutations in the four groups, we found a lower prevalence in microMTCs (pConclusions: The overall prevalence of RET somatic mutations was lower than expected, and the prevalence of the somatic M918T RET mutation was significantly lower in microMTCs than in larger tumors. To explain this finding, we can hypothesize either that other oncogene(s) might be responsible for the majority of microMTC, thus identifying a tumor subset, or that the RET mutation might, or might not, occur later during tumor progression.Keywords
This publication has 21 references indexed in Scilit:
- High Prevalence ofRASMutations inRET-Negative Sporadic Medullary Thyroid CarcinomasThe Journal of Clinical Endocrinology & Metabolism, 2011
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid CancerJournal of Clinical Oncology, 2009
- Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomasMolecular and Cellular Endocrinology, 2008
- Prognostic Significance of SomaticRETOncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up StudyThe Journal of Clinical Endocrinology & Metabolism, 2008
- RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine TumorsEndocrine Reviews, 2006
- A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995Cancer, 1998
- Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrenceThe Journal of Clinical Endocrinology & Metabolism, 1996
- Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomasThe Journal of Clinical Endocrinology & Metabolism, 1995
- Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumoursHuman Molecular Genetics, 1994
- Medullary Thyroid Carcinoma: Clinicopathologic Features and Long-Term Follow-Up of 65 Patients Treated During 1946 Through 1970Mayo Clinic Proceedings, 1992